Disproportionality Analysis of Amenamevir-Induced Encephalopathy Using the Japanese Adverse Drug Event Report Database 1
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:1341-321X
-
Container-title:Journal of Infection and Chemotherapy
-
language:en
-
Short-container-title:Journal of Infection and Chemotherapy
Author:
Yamada TomoyukiORCID,
Ogawa TakuORCID,
Tanaka Tomoko,
Kusaka Yusuke,
Nishihara Masami,
Ashida Akira
Reference23 articles.
1. Hansen N. Drug induced encephalopathy. In: Tanasescu R, editor. Miscellanea on Encephalopathies - A Second Look. Tech; 2012, p. 39–61, http://www.intechopen.com/books/miscellanea-on-encephalopathies-a-second-look/drug-induced-encephalopathy.
2. European consensus-based (S2k) Guideline on the Management of herpes zoster – Guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment;Werner;J Eur Acad Dermatol Venereol,2017
3. Recommendations for the management of herpes zoster;Dworkin;Clin Infect Dis,2007
4. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases;Brandariz-Nuñez;J Clin Pharm Ther.,2021
5. Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster;Shiraki;Viruses,2021